To our knowledge, this is the first multi-omics study to explore correlations between the use of antibiotics or probiotics, distribution characteristics and dynamic changes of gut microbiota, fecal metabolites, and immunotherapy efficacy among patients with advanced EGFR + NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.